Investor Presentaiton

Hematology Reblozyl BET Inhibitor Breyanzi golcadomide Abecma alnuctamab GPRC5D Addressing high unmet medical need in Hematology Asset SUSPENSION FOR IV INFUSION Approved 5L+ R/R MM¹ • Registrationalt 3L+ triple-class exposed MM Sub-optimal response post-SCT iber/mezi Exploratory/PoC Studiest Abecma [idecabtagene vicleucel) Breyanzi (lisocabtagene maraleucel); Reblozyl (luspatercept-aamt) for injection 25mg. 75mg SUSPENSION 2L LBCL • 3L+ LBCL FOR IV INFUSION 1L MDS . 2L TD MDS-RS alnuctamab BET Inhibitor (BMS-986158) iberdomide golcadomide GPRC5D CAR T mezigdomide • • R/R CLL/SLL R/R MCL • ⚫ 2L+ FL; 3L+ FL • R/R MZL TD & NTD² Beta Thalassemia 1L NTD MDS TD MF 2-4L MM . Alpha Thalassemia³ NDMM post-SCT maintenance Novel combinations in MM Novel combinations in MF • 2-3L MM 1L LBCL Quadruple-class exposed MM 2-4L MM 2L+ MM 1L DLBCL R/R PTCL4 Novel combinations 1. Approved in 4L+ ex-US; 2. NTD approved ex-U.S.; 3. Asia-only study; 4. Japan-only study; † ongoing or initiating 2023/2024 Ill Bristol Myers Squibb™ Not for Product Promotional Use 74

View entire presentation